🔗 Share this article

Ministers and senior MPs have issued warnings that the United Kingdom's series of deals with the US administration are "lacking a solid foundation." This follows revelations that a recently announced deal on drug pricing, which promises zero tariffs in exchange for the NHS facing higher prices, lacks any underlying contract beyond broad headline terms published in government press releases.

Lacking Legal Footing

The deal on drug tariffs, hailed as a "generational" achievement, remains an "broad understanding" without detailed provisions. Observers point out that the press releases from the UK and US governments describe the deal in divergent terms. The British version focuses on securing "zero per cent tariffs" as a unique achievement, while the American announcement concentrates on the expectation for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has agreed to terms to raise drug prices in return for only a assurance from President Trump," stated David Henig, a trade policy analyst. "It is documented he has a tendency for not honouring his word."

Broader Instability and a Paused Tech Deal

Worries have been intensified by Washington's recent decision to pause the £31bn "tech prosperity deal", which was previously heralded as "a transformative pact" in the bilateral relationship. The US pointed to a lack of progress from the UK on lowering trade barriers as the reason for the pause.

Furthermore, concessions secured for British farmers as part of an May trade agreement have still not been formally signed off by the US, despite a looming January deadline. "It is our belief that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have expressed concerns that the government's US-UK accords are unstable and unpredictable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, remarked: "Perhaps most shocking than the US approach is the UK government's naive belief that his administration is a reliable partner. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Officials have sought to reduce the possibility of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been lobbying for the agreement, desiring stability on imports and pricing, making it more concrete than the paused tech deal.

Officials admit that unpredictability is part and parcel of dealing with the current US leadership. However, they maintain that the UK has achieved real benefits for businesses, such as lower steel tariffs compared to other nations. "Securing 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

Yet, issues have surfaced in carrying out the initial US-UK accord. Promised quotas on beef exports have yet to be finalized, and the pledge to "eliminate duties on UK metals" has remains unmet, with tariffs fixed at 25%.

Moving forward, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.